Intraperitoneal chemotherapy in the management of malignant disease

Expert Review of Anticancer Therapy

Volumn 1, Issue 1, 2001, Pages 142-148

  Markman, Maurie ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

5 Fluorouracil; Carboplatin; Cisplatin; Gastrointestinal cancers; Intraperitoneal chemotherapy; Mitomycin c; Ovarian cancer; Paclitaxel; Peritoneal mesothelioma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; STREPTOZOCIN;

ADVANCED CANCER; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HUMAN; MINIMAL RESIDUAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; OUTCOMES RESEARCH; OVARY CANCER; PERITONEAL CAVITY; REVIEW; VOMITING;

EID: 0035559633     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.1.142     Document Type: Review

References (50)

1. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer
2. Theoretical and experimental bases of intraperitoneal chemotherapy
3. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration
4. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin
5. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity
6. Intraperitoneal cisplatin with systemic thiosulfate protection
7. Ip. cisplatin in patients with malignant ascites: Pharmacokinetics evaluation and comparison with the iv. route
8. Clinical pharmacology of intraperitoneal cisplatin
9. Pharmacokinetics of Ip. cisplatin in refractory ovarian carcinoma
10. Pharmacokinetics of carboplatin after intraperitoneal administration
11. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a Phase I study of the Northern California Oncology Group
12. Pharmacological data and technical feasibility of intraperitoneal 5-fluorouracil administration
13. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally
14. Portal levels and hepatic clearance of 5-flourouracil after intraperitoneal administration in humans
15. Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group Study
16. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study
17. Intraperitoneal therapy of ovarian cancer
18. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin
19. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: Lessons learned from a Gynecologic Oncology Group Phase II trial of IP cisplatin and recombinant α-interferon
20. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: A Gynecologic Oncology Group Study
21. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy
22. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids
23. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro
24. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer
25. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy
26. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube and peritoneum: A Gynecologic Oncology Group Study
27. A Phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high-risk colon cancer
28. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer
29. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: A University of Southern California Pilot Program
30. Neoadjuvant therapy of high-risk gastric cancer: A Phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil
31. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy
32. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer
33. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer
34. Peritoneal carcinomatosis from appendiceal cancer: Results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy
35. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy
36. Early peritoneal mesothelioma. A treatable malignancy
37. Long-term survival in peritoneal mesothelioma: The role of radiotherapy and combined modality treatment
38. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
39. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group
40. Tamoxifen for early breast cancer: An overview of the randomised trials
41. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
42. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer
43. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer
44. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: Results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology
45. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma
46. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer
47. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer
48. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer
49. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer
50. Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy